Download PDF
Laryngorhinootologie 2011; 90(10): 591-594
DOI: 10.1055/s-0031-1286302
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Entwicklungen bei der Erfassung der Lebensqualität mit Instrumenten der European Organisation for Research and Treatment of Cancer (EORTC)[*]

Current Developments in Measuring Quality of Life with Instruments of the European Organisation for Research and Treatment of Cancer (EORTC)
S. Singer
1   Abteilung Gesundheitspsychologie und Angewandte Diagnostik, Bergische Universität Wuppertal
2   Abteilung Medizinische Psychologie und Medizinische Soziologie, Universität Leipzig
,
D. Hofmeister
2   Abteilung Medizinische Psychologie und Medizinische Soziologie, Universität Leipzig
,
K. Spiegel
3   Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Friedrich-Schiller-Universität Jena
,
A. Boehm
4   Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Universitätsklinikum Leipzig
› Author Affiliations
Further Information

Publication History

Publication Date:
20 October 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Arbeitsgruppe Quality of Life der European Organisation for Research and Treatment of Cancer (EORTC) entwickelt seit vielen Jahren gemeinsam Lebensqualitätsfragebögen auf hohem methodischem Niveau. Diese Fragebögen werden vorrangig für die Anwendung in Klinischen Studien konzipiert. Aufgrund veränderter Behandlungsmodalitäten, die in klinischen Studien geprüft werden sollen, und aufgrund vereinzelter methodischer Kritik am bisherigen Modul wird der bisherige Fragebogen für die Kopf-Hals-­Tumorpatienten (EORTC QLQ-H&N35) im Moment überarbeitet.

In diesem Beitrag soll der Stand der Überarbeitung dargestellt und über weitere aktuelle Entwicklungen berichtet werden.

Abstract

Current Developments in Measuring Quality of Life with ­Instruments of the European Organisation for Research and Treatment of Cancer (EORTC)

Since many years, the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group develops and validates measures for the assessment of quality of life in cancer patients, using high standards of methodology. These questionnaires are meant to be used primarily in clinical trials.

As treatment strategies are changing and because of some ­methodological criticism, the head and neck module EORTC QLQ-H&N35 is currently being revised and updated.

In this paper, we will present the current state of work and other recent developments regarding the EORTC Quality of Life ques­tionnaire development.

Schlüsselwörter

Lebensqualität - Instrumente - EORTC - Validierung

Key words

Quality of Life - Instruments - EORTC - Validation
*

* Die Studie wird von der European Organisation for Research and Treatment of Cancer gefördert.


 

  • Literatur

  • 1 Aaronson N, Ahmedzai S, Bergmann B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F. for the EORTC Study Group on Quality of Life. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. J Nat Cancer Institute 1993; 85 (05) 365-376
    PubMedGoogle Scholar
  • 2 Björdal K, Ahlner-Elmqvist M, Tollesson E, Jensen AB, Razavi D, Maher EJ, Kaasa S. Development of an European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol 1994; 33 (08) 879-885
    CrossrefPubMedGoogle Scholar
  • 3 Björdal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, Evensen JF, Biorklund A, de LJ, Fayers PM, Jannert M, Westin T, Kaasa S. Quality of life in head and neck cancer patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999; 17 (03) 1008-1019
    CrossrefPubMedGoogle Scholar
  • 4 Björdal K, de Graeff A. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. Eur J Cancer 2000; 36: 1796-1807
    CrossrefPubMedGoogle Scholar
  • 5 Op de Coul BM, Ackerstaff AH, van As CJ, van den Hoogen FJ, Meeuwis CA, Manni JJ, Hilgers FJ. Quality of life assessment in laryngectomized individuals: do we need additions to standard questionnaires in specific clinical research projects?. Clinical Otolaryngology 2005; 30 (02) 169-175
    CrossrefPubMedGoogle Scholar
  • 6 Maune S, Bosse F, Heissenberg MC, Schmidt C, Berens M, Kuchler T. A concept for the assessment of quality of life in patients with carcinomas of the upper aerodigestive tract. HNO 2002; 50 (04) 347-353
    CrossrefPubMedGoogle Scholar
  • 7 Singer S, Wollbrück D, Wulke C, Dietz A, Klemm E, Oeken J, Meister EF, Gudziol H, Bindewald J, Schwarz R. Validation of the EORTC QLQ-C30 and EORTC QLQ-H&N35 in Laryngeal Cancer Patients after Surgery. Head and Neck 2009; 31 (01) 64-76
    CrossrefPubMedGoogle Scholar
  • 8 Zotti P, Lugli D, Vaccher E, Vidotto G, Franchin G, Barzan L. The EORTC quality of life questionnaire-head and neck 35 in Italian laryngectomized patients. European organization for research and treatment of cancer. Quality of Life Research 2000; 9 (10) 1147-1153
    CrossrefPubMedGoogle Scholar
  • 9 Sherman AC, Simonton S, Adams DC, Vural E, Owens B, Hanna E. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Archives of Otolaryngology – Head & Neck Surgery 2000; 126 (04) 459-467
    PubMedGoogle Scholar
  • 10 Hanna E, Sherman AC, Adams DC, Vural E, Fan C-Y, Suen JY. Quality of Life for Patients Following Total Laryngectomy vs Chemoradiation for Laryngeal Preservation. Arch Otolaryngol Head Neck Surg 2004; 130: 875-879
    CrossrefPubMedGoogle Scholar
  • 11 Guntinas-Lichius O, Rühlow S, Veelken F, Klussmann JP. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. Journal of Cancer Research and Clinical Oncology 2009; 135: 901-908
    CrossrefPubMedGoogle Scholar
  • 12 Brizel DM, Murphy B, Rosenthal DI, Pandya K, Glück S, Brizel H, Meredith R, Berger D, Chen M-G, Mendenhall W. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology 2008; 26 (15) 2489-2496
    CrossrefPubMedGoogle Scholar
  • 13 Abdel-Wahab M, Abitbol A, Lewin A, Troner M, Hamilton K, Markoe A. Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials 2005; 28 (04) 359-366
    PubMedGoogle Scholar
  • 14 Ackerstaff AH, Balm A, Rasch C, de Boer J, Wiggenraad R, Rietveld D, Gregor RT, Kröger R, Hilgers FJ. First-year quality of life assessment of an intra-arterial (radplat) versus intravenous chemoradiation phase III trial. Head and Neck 2009; 31: 77-84
    CrossrefPubMedGoogle Scholar
  • 15 Levendag PC, Teguh DN, Voet P, van der EH, Noever I, de Kruijf WJ, Kolkman-Deurloo IK, Prevost JB, Poll J, Schmitz PI, Heijmen BJ. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiotherapy & Oncology 2007; 85 (01) 64-73
    CrossrefPubMedGoogle Scholar
  • 16 Poulsen MG, Riddle B, Keller J, Porceddu SV, Tripcony L. Predictors of acute grade 4 swallowing toxicity in patients with stages III and IV squamous carcinoma of the head and neck treated with radiotherapy alone. Radiotherapy and Oncology 2008; 87 (02) 253-259
    CrossrefPubMedGoogle Scholar
  • 17 Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weickselbaum RR, Haraf DJ. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. Journal of Clinical Oncology 2003; 21 (02) 320-326
    CrossrefPubMedGoogle Scholar
  • 18 Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio RC, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris Jr CM, Haddad RI. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357 (17) 1705-1715
    CrossrefPubMedGoogle Scholar
  • 19 Rosenthal DI, Lewin JS, Eisbruch A. Prevention and Treatment of ­Dysphagia and Aspiration After Chemoradiation for Head and Neck Cancer. Journal of Clinical Oncology 2006; 24: 2636-2643
    CrossrefPubMedGoogle Scholar
  • 20 Curran D, Giralt J, Harari P, Ang K, Cohen R, Kies M, Jassem J, Baselga J, Rowinsky E, Amellal N, Comte S, Bonner J. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. Journal of Clinical Oncology 2007; 25 (16) 2191-2197
    CrossrefPubMedGoogle Scholar
  • 21 Jensen K, Jensen AB, Grau C. A cross sectional quality of life study of 116 recurrence free head and neck cancer patients. The first use of EORTC H&N35 in Danish. Acta Oncologica 2006; 45 (01) 28-37
    CrossrefPubMedGoogle Scholar
  • 22 Giesinger J, Kemmler G, Meraner V, Gamper EM, Oberguggenberger A, Sperner-Unterweger B, Holzner B. Towards the Implementation of Quality of Life Monitoring in Daily Clinical Routine: Methodological Issues and Clinical Implication. Breast Care 2009; 4 (03) 148-154
    CrossrefPubMedGoogle Scholar